

IFOPA
5.8K posts

@ifopa
Fund research to find a cure for FOP while supporting individuals and families through education, public awareness and advocacy.





We’re expanding our commitment to the rare disease community. Mirum has in-licensed exclusive worldwide rights to zilurgisertib, an investigational oral therapy in development for fibrodysplasia ossificans progressiva (FOP)—an ultra-rare genetic disease, from @Incyte. The FDA has accepted the NDA for zilurgisertib and granted Priority Review, with a PDUFA date of September 26, 2026. This moment reflects years of progress driven by the FOP community, and we’re honored to add our voice to that foundation. For patients living with FOP and their families, new treatment options cannot come soon enough. We’re committed to working with urgency to bring this potential therapy forward. #FOP #RareDisease































